Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Foretinib in Patients With Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer

NCT01147484 is registered in ClinicalTrials.gov with NCIC Clinical Trials Group as lead sponsor.

NCT NCT01147484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01147484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Foretinib in Patients With Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer
Lead sponsor
NCIC Clinical Trials Group
Phase
Phase 2
Overall status
Completed
Start date
September 2, 2010
Completion date
February 13, 2015
Enrollment
47 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent breast cancer